Ha Eun Ju, Lee Min Kyoung, Baek Jung Hwan, Lim Hyun Kyung, Ahn Hye Shin, Baek Seon Mi, Choi Yoon Jung, Chung Sae Rom, Kim Ji-Hoon, Shin Jae Ho, Lee Ji Ye, Hong Min Ji, Kim Hyun Jin, Joo Leehi, Hahn Soo Yeon, Jung So Lyung, Lee Chang Yoon, Lee Jeong Hyun, Lee Young Hen, Park Jeong Seon, Shin Jung Hee, Sung Jin Yong, Choi Miyoung, Na Dong Gyu
Department of Radiology, Ajou University School of Medicine, Suwon, Republic of Korea.
Department of Radiology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Korean J Radiol. 2025 Jan;26(1):10-28. doi: 10.3348/kjr.2024.0963.
Radiofrequency ablation (RFA) is a minimally invasive treatment modality used as an alternative to surgery in patients with benign thyroid nodules, recurrent thyroid cancers (RTCs), and primary thyroid microcarcinomas. The Korean Society of Thyroid Radiology (KSThR) initially developed recommendations for the optimal use of RFA for thyroid tumors in 2009 and revised them in 2012 and 2017. As new meaningful evidence has accumulated since 2017 and in response to a growing global interest in the use of RFA for treating malignant thyroid lesions, the task force committee members of the KSThR decided to update the guidelines on the use of RFA for the management of RTCs based on a comprehensive analysis of current literature and expert consensus.
射频消融术(RFA)是一种微创治疗方式,可替代手术用于治疗良性甲状腺结节、复发性甲状腺癌(RTC)和原发性甲状腺微小癌患者。韩国甲状腺放射学会(KSThR)于2009年首次制定了甲状腺肿瘤射频消融术最佳应用的建议,并于2012年和2017年进行了修订。自2017年以来,随着新的有意义证据的积累,以及全球对射频消融术治疗恶性甲状腺病变的兴趣日益增加,KSThR的特别工作组委员会成员决定在对当前文献进行全面分析和专家共识的基础上,更新关于射频消融术治疗复发性甲状腺癌的管理指南。